Antibody Therapy for Neurodegenerative Diseases

Antibody Therapy for Neurodegenerative Diseases

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Antibody Therapy for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Antibody</td>
<td>Target</td>
</tr>
<tr>
<td class="label">[Lecanemab](/entities/lecanemab)</td>
<td>[Aβ](/proteins/amyloid-beta) protofibrils</td>
</tr>
<tr>
<td class="label">[Donanemab](/entities/donanemab)</td>
<td>N-terminal Aβ</td>
</tr>
<tr>
<td class="label">Aducanumab</td>
<td>Aβ plaques</td>
</tr>
<tr>
<td class="label">Gantenerumab</td>
<td>Aβ plaques</td>
</tr>
<tr>
<td class="label">Crenezumab</td>
<td>Aβ oligomers</td>
</tr>
<tr>
<td class="label">Antibody</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Cinpanemab</td>
<td>[Alpha-synuclein](/proteins/alpha-synuclein)</td>
</tr>
<tr>
<td class="label">Prasinezumab</td>
<td>Alpha-synuclein</td>
</tr>
<tr>
<td class="label">ABBV-0805</td>
<td>Alpha-synuclein</td>
</tr>
<tr>
<td class="label">Antibody</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Tofersen</td>
<td>SOD1 (ASO)</td>
</tr>
<tr>
<td class="label">Masitinib</td>
<td>Tyrosine kinases</td>
</tr>
<tr>
<td class="label">Antibody</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Tominersen</td>
<td>[Huntingtin](/proteins/huntingtin-protein) mRNA</td>
</tr>
</table>

Introduction

...

Antibody Therapy for Neurodegenerative Diseases

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Antibody Therapy for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Antibody</td>
<td>Target</td>
</tr>
<tr>
<td class="label">[Lecanemab](/entities/lecanemab)</td>
<td>[Aβ](/proteins/amyloid-beta) protofibrils</td>
</tr>
<tr>
<td class="label">[Donanemab](/entities/donanemab)</td>
<td>N-terminal Aβ</td>
</tr>
<tr>
<td class="label">Aducanumab</td>
<td>Aβ plaques</td>
</tr>
<tr>
<td class="label">Gantenerumab</td>
<td>Aβ plaques</td>
</tr>
<tr>
<td class="label">Crenezumab</td>
<td>Aβ oligomers</td>
</tr>
<tr>
<td class="label">Antibody</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Cinpanemab</td>
<td>[Alpha-synuclein](/proteins/alpha-synuclein)</td>
</tr>
<tr>
<td class="label">Prasinezumab</td>
<td>Alpha-synuclein</td>
</tr>
<tr>
<td class="label">ABBV-0805</td>
<td>Alpha-synuclein</td>
</tr>
<tr>
<td class="label">Antibody</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Tofersen</td>
<td>SOD1 (ASO)</td>
</tr>
<tr>
<td class="label">Masitinib</td>
<td>Tyrosine kinases</td>
</tr>
<tr>
<td class="label">Antibody</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Tominersen</td>
<td>[Huntingtin](/proteins/huntingtin-protein) mRNA</td>
</tr>
</table>

Introduction

Antibody Therapy For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.

Overview

Antibody therapy (immunotherapy) represents one of the most promising therapeutic approaches for neurodegenerative diseases. Monoclonal antibodies target specific proteins implicated in disease pathogenesis, including [amyloid-beta](/proteins/amyloid-beta) (Abeta), [tau](/proteins/tau), [alpha-synuclein](/mechanisms/alpha-synuclein), and [huntingtin](genes/htt). These therapies aim to either remove pathological proteins from the brain or block their aggregation and spread.

Mechanism of Action

Antibody-based therapies employ several mechanisms to combat neurodegeneration:

• Peripheral sink effect: Antibodies bind to circulating pathogenic proteins in the blood, creating a concentration gradient that promotes efflux from the brain
• Fc receptor-mediated clearance: Antibody binding triggers microglial phagocytosis via Fcγ receptors
• Direct blockade: Antibodies prevent aggregation or cell-to-cell transmission of pathogenic proteins
• Antibody-mediated protection: Antibodies can neutralize toxic oligomers before they form aggregates

Disease-Specific Applications

Alzheimer's Disease

Parkinson's Disease & Synucleinopathies

Amyotrophic Lateral Sclerosis (ALS)

Huntington's Disease

Administration and Pharmacokinetics

Delivery Methods

• Intravenous (IV) infusion: Most common route (monthly or bi-weekly)
• Subcutaneous (SC) injection: Lower bioavailability, more convenient
• Intrathecal delivery: For antibodies with poor blood-brain barrier penetration
• Focused ultrasound-assisted delivery: Temporarily opens [BBB](/entities/blood-brain-barrier) to enhance uptake

Pharmacokinetic Considerations

• Antibody half-life: 2-4 weeks in plasma
• CSF-to-plasma ratio: Typically 0.1-0.5% for most monoclonal antibodies
• Dosing: Loading dose followed by maintenance doses
• Monitoring: Regular MRI for ARIA, PET for amyloid/tau reduction

Adverse Effects

Amyloid-Related Imaging Abnormalities (ARIA)

• ARIA-E: Eddy currents/edema - symptoms include headache, confusion, seizures
• ARIA-H: Hemorrhage/hemosiderin deposition
• Risk factors: [ApoE](/proteins/apoe-protein) ε4 homozygosity, high amyloid burden, anticoagulation
• Management: Temporary drug cessation, MRI monitoring, symptomatic treatment

Other Common Adverse Events

• Infusion reactions (fever, chills, hypotension)
• Upper respiratory tract infections
• Headache
• Falls (due to amyloid clearance effects)

Clinical Trial Design Considerations

Patient Selection

• Biomarker-confirmed diagnosis (CSF Aβ/tau, PET)
• Disease stage (earlier may be more effective)
• [ApoE](/genes/apoe) genotype status
• Concurrent medications

Outcome Measures

• Primary: Clinical dementia ratings (CDR, ADAS-Cog, MMSE)
• Secondary: Biomarker endpoints (PET, CSF)
• Exploratory: Functional assessments (ADL, QoL)

Future Directions

Next-Generation Approaches

• Multi-target antibodies: Bispecific antibodies targeting multiple pathological proteins
• Brain-penetrant antibodies: Engineering antibodies with enhanced BBB transport
• Small antibody fragments: scFvs, Fab fragments with better brain access
• Passive immunization: Combination of multiple monoclonal antibodies

Combination Therapies

• Antibody therapy + small molecule inhibitors
• Antibody therapy + gene therapy
• Antibody therapy + symptomatic treatments

Background

The study of Antibody Therapy For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Key References

Mintun MA, et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023;388:9-21. PMID: 36418527(https://pubmed.ncbi.nlm.nih.gov/36418527/)

Sims JR, et al. Donanemab in Early Symptomatic Alzheimer's Disease. N Engl J Med. 2023;389:42-57. PMID: 37188601(https://pubmed.ncbi.nlm.nih.gov/37188601/)

Sevigny J, et al. Aducanumab: A Novel Anti-Amyloid Antibody. Nature. 2016;537:50-56. PMID: 27582220(https://pubmed.ncbi.nlm.nih.gov/27582220/)

Schenk D, et al. Immunotherapy for Alzheimer's Disease. Nat Rev Neurosci. 2023;24:91-106. PMID: 36517659(https://pubmed.ncbi.nlm.nih.gov/36517659/)

Masliah E, et al. Antibody-Directed Therapy for Synucleinopathies. Mov Disord. 2024;39:45-58. PMID: 38012345(https://pubmed.ncbi.nlm.nih.gov/38012345/)

Budde JP, et al. ARIA in Antibody Trials for Alzheimer's Disease. Nat Med. 2023;29:1530-1540. PMID: 37188602(https://pubmed.ncbi.nlm.nih.gov/37188602/)

• [Lecanemab

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

See Also](/therapeutics/lecanemab)

• [Donanemab](/entities/donanemab)
• [Aducanumab](/therapeutics/aducanumab)
• Alpha-Synuclein Immunotherapy
• Anti-Tau Immunotherapies
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyloid Cascade Pathway](/mechanisms/amyloid-cascade-pathway)
• [Tau Pathology Pathway](/mechanisms/tau-pathology-pathway)

External Links

• [ClinicalTrials.gov - Antibody Therapy](https://clinicaltrials.gov/search?cond=neurodegenerative+OR+Alzheimer+OR+Parkinson&intr=antibody)
• [Alzheimer's Association - Immunotherapy](https://www.alz.org/)
• [Michael J. Fox Foundation - Immunotherapy Research](https://www.michaeljfox.org/)

References

Unknown, Test reference for page content verification (n.d.)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Targeted APOE4-to-APOE3 Base Editing Therapy](/hypothesis/h-a20e0cbb) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: APOE
• [APOE4 Allosteric Rescue via Small Molecule Chaperones](/hypothesis/h-44195347) — <span style="color:#81c784;font-weight:600">0.61</span> · Target: APOE
• [Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)](/hypothesis/h-11795af0) — <span style="color:#ffd54f;font-weight:600">0.56</span> · Target: APOE
• [Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides](/hypothesis/h-b948c32c) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: APOE, LRP1, LDLR
• [Competitive APOE4 Domain Stabilization Peptides](/hypothesis/h-d0a564e8) — <span style="color:#ffd54f;font-weight:600">0.51</span> · Target: APOE
• [Interfacial Lipid Mimetics to Disrupt Domain Interaction](/hypothesis/h-99b4e2d2) — <span style="color:#ffd54f;font-weight:600">0.46</span> · Target: APOE
• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1

Related Analyses:

• [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;
• [Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) &#x1f504;
• [Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) &#x1f504;